Barclays lowered the firm’s price target on Humana (HUM) to $176 from $245 and keeps an Equal Weight rating on the shares. The firm is ‘incrementally cautious” on the company’s expectation that Individual Medicare Advantage margins will double.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana: Uncertain Margin Recovery and Star Rating Headwinds Drive Neutral ‘Hold’ Stance
- Humana price target lowered to $206 from $290 at Wells Fargo
- Humana price target lowered to $200 from $285 at Truist
- Humana price target lowered to $173 from $260 at TD Cowen
- Humana price target lowered to $180 from $231 at Deutsche Bank